Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Kintor Pharmaceutical Limited (KNTPF)
Suzhou, CN
Kintor Pharmaceutical Limited is a clinical-stage biotechnology firm dedicated to the development and commercialization of a diverse pipeline of small molecule and biologic treatments. Its primary focus is on addressing androgen-receptor-related conditions where current medical options are lacking, serving patients both within the People's Republic of China and globally. The company's innovative pipeline features several key candidates, such as Proxalutamide, a next-generation androgen receptor (AR) antagonist currently being investigated for metastatic castration-resistant prostate cancer, AR-positive breast cancer, and COVID-19. Another notable compound is Pyrilutamide, also an AR antagonist, designed to treat androgenetic alopecia (AGA) and acne vulgaris. Kintor also has an ALK-1 antibody in its portfolio, aimed at metastatic hepatocellular carcinoma (HCC) and various other solid tumors. Additionally, GT20029, a topical AR-PROTAC compound, is under development for AGA and acne vulgaris. A dual-target antibody, PD-L1/TGF-ß, is being explored for its potential in treating non-small cell lung cancer, biliary tract cancer, triple-negative breast cancer, and HPV-associated tumors. Further contributing to its diverse offerings is Detorsertib, intended for metastatic solid tumors including breast, prostate, and HCC. Finally, a Hedgehog/SMO Inhibitor, which targets the hedgehog signal transduction pathway, is being developed for blood cancer and basal-cell carcinoma. Established in 2009, Kintor Pharmaceutical Limited maintains its headquarters in Suzhou, People's Republic of China.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | -23.31% | -26.96% | -31.58% | -0.15% | +24.26% | +51.30% | -56.17% | -92.92% | -78.22% | -78.22% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
-
Revenue growth Biotechnology: +1.6%+536.8% ★
-
EPS growth Biotechnology: +29.7%-19.4% Q4'25: +87.4% (vs Q4'23)
-
FCF margin FCF growth · Biotechnology: +16.2%-595.8% Q4'25: -379.7% (vs Q4'23)
-
EBIT margin Biotechnology: +0.0%-619.9% Q4'25: -450.5% (vs Q4'23)
-
ROIC Biotechnology: -16.1%-84.1% Q4'25: -197.3% (vs Q4'23)
-
Share dilution Biotechnology: -3.4%+4.4% Q4'25: +7.4% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.53× Q4'25: -0.22× (vs Q4'23)
| Metric |
Dec 2020 actual |
Dec 2024 actual |
Dec 2025 actual |
|---|---|---|---|
| Revenue |
—
est: 332.6K (-100.0%)
|
5.00M
est: 102.96M (-95.1%)
|
31.84M
est: 387.87M (-91.8%)
|
| EBITDA |
-396.33M
est: 66.5K (-595,899.8%)
|
-128.37M
est: -20.59M (-523.4%)
|
-165.00M
est: -77.57M (-112.7%)
|
| EBIT |
-399.74M
est: 66.5K (-601,036.6%)
|
-146.00M
est: -20.59M (-609.0%)
|
-197.36M
est: -77.57M (-154.4%)
|
| Net Income |
-508.30M
est: -3.48B (+85.4%)
|
-155.29M
est: -804.81M (+80.7%)
|
-194.94M
est: -620.48M (+68.6%)
|
| SGA |
85.69M
est: 1.49M (+5,645.6%)
|
88.38M
est: 513.39M (-82.8%)
|
111.76M
est: 1.93B (-94.2%)
|
| EPS |
-1.64
est: -8.08 (+79.7%)
|
-0.36
est: -1.79 (+79.9%)
|
-0.43
est: -1.38 (+68.8%)
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-28 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-26 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-18 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-15 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-11 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-05 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-27 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-20 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Youzhi Tong | Founder, Chief Executive Officer & Executive Chairman | 682.4K | — |
| Xiang Ni | Chief Medical Officer & Executive Director | 499.3K | — |
| Ming Ming Cheung | Joint Company Secretary & Chief Financial Officer | — | male |
| Wai Chiu Wong | Company Secretary | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for KNTPF
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
